Novel theta defensin analogs
Synthetic theta-defensin analogs with a 14-amino acid structure and two disulfide bonds address the limitations of current sepsis treatments by recruiting immune cells and modulating inflammation, enhancing survival in sepsis models and offering potential applications in chronic inflammatory and viral diseases.
Patent Information
- Application Number
- JP2024168262
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-06-26
- Filing Date
- 2024-09-27
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for sepsis and septic shock, such as antibiotics and vasoconstrictors, have high morbidity and mortality rates, and existing defensin-based therapies pose safety concerns due to pro-inflammatory cytokine stimulation.
Development of synthetic theta-defensin analogs with a specific 14-amino acid structure and two disulfide bonds, which recruit immune effector cells and modulate inflammatory responses, providing a biphasic effect to combat infections and sepsis/septic shock without direct antimicrobial activity.
The theta-defensin analogs effectively reduce mortality and improve long-term survival in sepsis models by recruiting immune cells and mitigating inflammation, even at sub-antimicrobial concentrations, with potential applications in treating chronic inflammatory conditions and viral diseases.
Smart Images

Figure 2024169717000001_ABST
Abstract
Description
[Technical field]
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 867,000, filed June 26, 2019. This and all other referenced external materials are incorporated herein by reference in their entirety. In the event that a definition or use of a term in a reference incorporated by reference conflicts or is contrary to the definition of that term provided herein, the definition of that term provided herein shall control.
[0002] FIELD OF THEINVENTION The field of the invention is biologics, in particular peptide drugs. [Background technology]
[0003] The Background Description contains information that may be helpful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0004] The body's defensive inflammatory response can sometimes lead to injury and even death. For example, sepsis and septic shock are the result of an inflammatory immune response. Treatment of septic shock is primarily by administering antibiotics and providing supportive care and vasoconstrictors to stabilize blood pressure. However, morbidity remains significant. Mortality from such inflammatory responses ranges from approximately 30% in sepsis to approximately 80% in septic shock. Thus, there is great interest in identifying therapeutic compounds that are effective in treating various aspects of sepsis and septic shock.
[0005] Defensins are a diverse family of small antimicrobial proteins that are part of the body's nonspecific defense against infection. There are three different, structurally distinct classes of defensin proteins: alpha, beta, and theta defensins. α- and β-defensins are linear, tridisulfide-containing peptides with molecular weights of approximately 2.6 kDa or 4.5 kDa, respectively. In contrast, θ-defensins are cyclic peptides (i.e., cyclic peptides whose backbone is formed by successive peptide bonds with no free amino or carboxyl termini) composed of 18 amino acids.
[0006] θ-defensins are expressed in tissues of rhesus macaques, baboons, and other Old World monkeys. They are absent in humans and other great apes. Naturally occurring θ-defensins consist of 18-backbone cyclized (i.e., via the alpha amine group rather than via a side chain moiety) peptides stabilized by three disulfide bonds. These three disulfide bonds are conserved among all known θ-defensins. θ-defensins were first discovered and classified as defensins based on the peptide's antimicrobial properties. More recently, it has been discovered that θ-defensins may have potent immunomodulatory effects.
[0007] US Patent No. 5,399,633 (Leherer et al.) describes the relationship between structure and biological activity of retrocyclin peptides and peptide analogs of such peptides containing various degrees of enantiomeric content in an attempt to derive structure / activity relationships, although these analogs retain the length and structure of the native retrocyclin. Furthermore, this document only provides references to antibacterial activity.
[0008] Peptide analogues of various defensins have been investigated. For example, US Pat. No. 5,999,433 (Colavita et al.) describes cyclic analogues of β-defensins that have improved antibiotic efficacy compared to the parent protein. However, such β-defensins have been shown to stimulate the release of proinflammatory cytokines, which raises safety concerns and limits their usefulness.
[0009] US Patent No. 5,999, 119 (Maury et al.) describes the synthesis and biological activity of chimeric θ-defensins and speculates on the possibility of making conservative amino acid substitutions, but which appear to retain the length and structure of native θ-defensins. US Patent No. 5,999, 119 (Selsted et al.) describes several tetradecapeptide θ-defensin analogs derived from RTD-1 and their biological properties.
[0010] Thus, there remains a need for safe and effective compounds for the management and / or treatment of sepsis / septic shock and physiologically relevant disorders resulting from a dysregulated inflammatory response. [Prior art documents] [Patent documents]
[0011] [Patent Document 1] International Publication No. 2007 / 044998 [Patent Document 2] European Patent Application Publication No. 2990415 [Patent Document 3] US Patent Application Publication No. 2003 / 0022829 [Patent Document 4] U.S. Pat. No. 10,512,669 Summary of the Invention
[0012] The present invention relates to synthetic analogs of theta-defensins which, compared to natural theta-defensins, have improved activity in treating sepsis and / or septic shock at concentrations lower than those at which the analogs have a direct bactericidal and / or bacteriostatic effect.
[0013] One embodiment of the inventive concept is a cyclic peptide consisting of 14 amino acids and having a structure including two disulfide bonds between two pairs of cysteines as shown in FIG. 2A. In such peptide, AA3 and AA12 are cysteines linked by disulfide bonds, AA5 and AA10 are cysteines linked by disulfide bonds, AA4 is a first hydrophobic amino acid, AA11 is a second hydrophobic acid, AA6 is arginine, AA7 is arginine, and AA8 is arginine. The cyclic peptide has a total of four arginine residues providing a positive charge amount of about 28% at physiological pH. The first hydrophobic amino acid and the second hydrophobic amino acid can be leucine or isoleucine. AA1 can be glycine. AA2 can be a third hydrophobic amino acid such as valine or phenylalanine. AA9 can be a fourth hydrophobic amino acid such as valine or phenylalanine. AA13 can be glycine. AA14 can be arginine. In some embodiments, AA4 cannot be alanine or serine. In some embodiments, AAl1 cannot be alanine or serine. In some embodiments, the cyclic peptide is MTD12813 (SEQ ID NO:2).
[0014] Such cyclic peptides can be analogs of θ-defensin that improve survival when applied systemically to a mouse model of sepsis compared to θ-defensin itself. In some embodiments, the cyclic peptides provide a biphasic response when applied to a mouse model of sepsis. Such a biphasic response includes a first phase of recruitment of host effector cells with antimicrobial activity and a second phase of alleviation of the host inflammatory response. In some embodiments, the cyclic peptides have TACE inhibitory activity and / or suppress at least one of TNF expression, processing, and release.
[0015] Such cyclic peptides retain activity after exposure to extreme temperatures, low pH, freezing and / or thawing, and dissolution in biological matrices (blood, plasma, serum, etc.). In some embodiments, such cyclic peptides are non-immunogenic at doses effective to treat or prevent sepsis and / or septic shock. Such cyclic peptides can activate the host immune system to promote host pathogen clearance, and can have activity to modulate inflammation, enhance disease resolution, and enhance survival at doses effective to treat or prevent septic shock.
[0016] Another embodiment of the inventive concept is a method of treating or preventing septic shock by administering to an animal at risk of septic shock a cyclic peptide as described above. Another embodiment of the inventive concept is the use of a cyclic peptide as described above in the treatment or prevention of sepsis and / or septic shock, or the use of such a cyclic peptide in the preparation of a medicament effective for the treatment or prevention of septic shock.
[0017] Various objects, features, aspects and advantages of the present subject matter will become more apparent from the following detailed description of the preferred embodiments and the accompanying drawings, in which like numerals represent like elements. [Brief description of the drawings]
[0018] [Figure 1] Figure 1 shows a schematic diagram of exemplary cyclic peptides referred to throughout. RTD-1 (SEQ ID NO:1) is a naturally occurring octadecapeptide θ-defensin. The remaining peptides are θ-defensin analogs. [Figure 2A] FIG. 2A shows a schematic diagram of a cyclic defensin analog, showing the numerical designation of amino acids by position along the cyclic chain. [Figure 2B] FIG. 2B provides an example of the application of these designations to the amino acids of the MTD12813 (SEQ ID NO:2) peptide. [Diagram 3] 1 shows the results of an efficacy study of macrocyclic peptides in a carbapenem-resistant Klebsiella pneumoniae sepsis model in mice. [Figure 4] 1 shows the results of an efficacy study of MTD12813 (SEQ ID NO: 2) in a carbapenem-resistant Klebsiella pneumoniae sepsis model in mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] Detailed Description The subject matter of the present invention provides novel peptides that induce a biphasic effect in treating infections and / or sepsis by first recruiting effector cells of the immune system to combat infectious organisms and then modulating the immune system to suppress systemic inflammatory responses such as those seen in sepsis and septic shock. The novel peptides are analogs of naturally occurring θ-defensins with modified sequences to provide an indirect antimicrobial effect via recruitment of effector cells of the host immune system to prevent and / or treat sepsis / septic shock. These novel θ-defensin analogs are effective at sub-antibacterial plasma concentrations that do not provide a direct antimicrobial effect (i.e., do not produce a bactericidal or bacteriostatic effect) in the absence of host innate immune effectors. Such θ-defensin analogs are protective at concentrations where native θ-defensins have no apparent effect and contain a core set of structural and sequence features not found in native θ-defensins.
[0020] In the context of this application, a "sub-antimicrobial" concentration should be understood to be a concentration at which the compound so described has no antimicrobial effect when applied to a representative microbial pathogen in vitro (e.g., in liquid medium), e.g., in the absence of host immune effectors. For example, a sub-antimicrobial concentration of a compound with respect to Klebsiella pneumoniae may be a concentration lower than the concentration that exhibits an antimicrobial effect against the organism in an in vitro setting (e.g., in the absence of host immune effectors). Such sub-antimicrobial concentrations can be determined experimentally (e.g., by culture from patient samples) or, preferably, from historical data.
[0021] The following description includes information that may be useful in understanding the present invention. This is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0022] In some embodiments, the numbers expressing properties such as amounts of ingredients, concentrations, reaction conditions, and the like, used to describe and claim certain embodiments of the present invention should be understood as being modified in some cases by the term "about". Thus, in some embodiments, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters must be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the present invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the present invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0023] As used throughout the description and claims, the meanings of "a," "an," and "the" include plural references unless the context clearly indicates otherwise. Also, as used throughout the description, the meaning of "in" includes "in" and "on," unless the context clearly indicates otherwise.
[0024] Grouping of alternative elements or embodiments of the invention disclosed herein should not be construed as limiting. Each group member may be referenced and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group may be included in or deleted from a group for reasons of convenience and / or patentability. When such inclusion or deletion occurs, the specification includes the group so modified, and accordingly, all Markush groups used in the appended claims are deemed to be set forth in the detailed description of the invention.
[0025] The recitation of ranges of values herein is merely intended to serve as a shorthand method of individually referencing each value within the range. Unless otherwise stated herein, each value is incorporated into the specification as if it were individually set forth herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "etc.") provided with respect to specific embodiments herein is intended merely to better illuminate the invention and does not otherwise limit the scope of the invention as claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0026] The following description provides a number of exemplary embodiments of the subject matter of the present invention. Although each embodiment represents a single combination of the elements of the present invention, the subject matter of the present invention is considered to include all possible combinations of the elements disclosed. Thus, if one embodiment includes elements A, B, and C, and a second embodiment includes elements B and D, the subject matter of the present invention is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.
[0027] It should be appreciated that the disclosed peptides provide many advantageous technical effects, including providing a biphasic response effective in reducing mortality from sepsis / septic shock when administered in small, sub-antimicrobial amounts.
[0028] The inventors have described synthetic cyclic tetradecapeptide analogs of theta defensin RTD-1, which, despite their smaller size and fewer disulfide bonds, have displayed some of the activity of the parent peptide. The structures of native theta defensin RTD-1 (SEQ ID NO:1) and several exemplary synthetic cyclic tetradecapeptide analogs are shown in FIG. 1. As shown, RTD-1 (naturally expressed in rhesus monkeys) is a cyclic octadecapeptide that contains three pairs of cysteines linked by disulfide bonds that span the cyclic primary structure of the peptide. Several examples of synthetic (i.e., non-naturally occurring) analogs of RTD-1 are shown. Each of the exemplary synthetic analogs is a tetradecapeptide that contains two pairs of cysteines linked by disulfide bonds. These disulfide bonds span the cyclic primary structure of the synthetic peptide to form a "box" substructure that incorporates additional amino acids. It is understood that these exemplary analogs exhibit varying degrees of sequence identity with RTD-1 and, in some cases, conservative amino acid substitutions near and between the "boxes" defined by the cysteines of the synthetic peptide analogs.
[0029] The present inventors have prepared and screened a series of θ-defensin analogs based on a synthetic peptide called MIDI280 (see FIG. 1, SEQ ID NO: 3), which provides substantially improved effects on long-term survival of mice in a sepsis model (compared to RTD-1), and which provides these effects at surprisingly low concentrations. It will be appreciated that long-term survival in sepsis requires management of both the infecting organism and the shock induced by the host's response to the infection, both of which can result in death.
[0030] Although examples of activity against sepsis and / or septic shock are provided, the inventors believe that the θ-defensin analogs described herein may also be effective in treating a variety of conditions resulting from dysregulated immune or inflammatory responses, including chronic conditions, examples of such chronic diseases include rheumatoid arthritis and inflammatory bowel disease.
[0031] Since θ-defensins have been found to have antiviral activity, the inventors believe that θ-defensin analogs of the inventive concept may similarly provide antiviral activity and may prove useful in treating viral disease and the inflammatory sequelae of viral infection. Such treatment includes prophylaxis and / or active disease. In some embodiments, the active disease so treated is symptomatic. In other embodiments, the active disease so treated is asymptomatic.
[0032] Surprisingly, θ-defensin analogs have been identified that provide a biphasic response in modulating the immune system. The first effect is opsonization, recruiting effector cells to the site of sepsis. This helps to fight infection and was surprisingly found to occur at concentrations of θ-defensin analogs that did not exhibit bactericidal or bacteriostatic effects (i.e., sub-antibacterial concentrations). Following this initial opsonization effect, these synthetic θ-defensin analogs exhibit long-term immunomodulatory effects (e.g., reduction of TNF, IL-6 and other inflammatory cytokines) that contribute to long-term survival in preventing septic shock.
[0033] As mentioned above, examples of naturally occurring θ-defensins and exemplary θ-defensin analogs are shown in FIG. 1. It should be understood that these are cyclic peptides lacking traditional amino and carboxyl termini. Therefore, the amino acid sequence information as set forth in the accompanying amino acid sequence listing should not be interpreted as being based on individual N- or C-termini. The primary structure of naturally occurring θ-defensin RTD-1 (SEQ ID NO: 1) is shown at the top of FIG. 1. The remaining peptides are exemplary non-natural analogs of θ-defensins. It should be understood that in the 14 amino acid analog series, their three-dimensional structure includes a first β-turn formed by amino acids 6-9 and a second β-turn formed by amino acids 13, 14, 1, and 2, as designated using the numbering system adapted for use with cyclic θ-defensins and their analogs as shown in FIGS. 2A and 2B.
[0034] Although these cyclic peptides do not have free amino or carboxyl termini, amino acid positions within the cyclic structure can be designated based on their position relative to certain structural features (such as disulfide bonds and / or the characteristic "triplet" of arginine). A set of such designations utilized for this purpose within the scope of this application is shown in FIG. 2A, where amino acids are designated 1-14 (AA1, AA2, etc.) in a cyclic tetradecapeptide structure having a cyclic and continuous chain of peptide bonds through the primary amines of the individual amino acids (i.e., not through side groups). Also, two intrapeptide covalent bonds occur between the side chains of cysteine amino acids designated as AA3 and AA12 and between the side chains of cysteine amino acids designated as amino acids AA5 and AA10. FIG. 2B illustrates the application of amino acid positions within the context of this application as applied to an exemplary synthetic cyclic tetradecapeptide (MTD12813 peptide, SEQ ID NO:2). Amino acid identities are designated using the one-letter amino acid code.
[0035] FIG. 3 shows the results of application of RTD-1 (SEQ ID NO: 1) and an exemplary novel synthetic tetradecapeptide in a mouse model of sepsis utilizing antibiotic-resistant bacteria that results in 75% mortality (i.e., 25% survival) if untreated. BALB / c mice were cultured with 3-5×10 8 CFU of a carbapenem-resistant strain of Klebsiella pneumoniae (KPC+-KpBAA-1705 (ATCC)) were infected intraperitoneally and treated with peptides 1 h after infection. The left panel of Figure 3 shows an exemplary result of a comparative study between the synthetic peptide MTD12813 (SEQ ID NO: 2) and the naturally occurring RTD-1 administered at 5 mg / kg. The right panel of Figure 3 shows an exemplary result of a comparative study between the synthetic peptides MTD12813 and MTD1280 (SEQ ID NO: 3) administered at 0.5 mg / kg. P values were determined by Fisher's exact test. Therapeutic peptides were provided intraperitoneally 1 h after induction of sepsis.
[0036] As shown in the left panel of Figure 3, RTD-1 (SEQ ID NO: 1) at 5 mg / kg provides only partial protection (70% survival vs. 25% for sham controls), whereas MTD12813 (SEQ ID NO: 2) provides complete protection from sepsis and septic shock. As shown in the right panel of Figure 3, at 0.5 mg / kg, the effect of MTD1280 (SEQ ID NO: 3) on survival is essentially identical to that of sham controls, whereas MTD12813 provides nearly 90% survival. This difference is highly significant (P=0.0031).
[0037] It should be understood that at these doses, θ-defensins and / or analogs thereof do not produce sufficient drug Cmax to have a noticeable direct antibacterial (e.g., bactericidal, bacteriostatic) effect. Without wishing to be bound by theory, the inventors believe that the antibacterial effect of MTD12813 (SEQ ID NO: 2), characteristic of the first phase of the biphasic response, is the result of a systemic immune activation mechanism that results in the recruitment and stimulation of cells from the host immune system, which then phagocytose, kill and eliminate pathogens. Furthermore, MTD12813 mitigates the inflammatory response, reducing the harmful effects of over-activated and / or unresolved systemic inflammation, such as cytokine storm.
[0038] Figure 4 shows typical results of a survival study in such a mouse survival study for various concentrations of MTD12813 (SEQ ID NO: 2) using the same mouse sepsis model used in the study shown in Figure 3. BALB / c mice were infected intraperitoneally with KPC+-Kp BAA-1705 (ATCC) and treated with a single dose of MTD12813 at the indicated levels 1 hour after infection. The significance of the therapeutic effect of each dose (P value determined by Fisher's exact test) is shown. As shown, 1.25 mg / kg of this novel θ-defensin analog is as effective as 5 mg / kg, and doses as low as 0.5 mg / kg of MTD12813 are also highly effective. It should be understood that 0.5 mg / kg was the lowest dose tested and the inventors believe that MTD12813 would be effective down to lower doses, e.g., 0.25 mg / kg, 100 μg / kg, 50 μg / kg, 25 μg / kg, or 10 μg / kg.
[0039] As described above, MTD12813 (SEQ ID NO:2) was identified in a screening study of a series of cyclic peptide analogs of the theta-defensin RTD-1 (SEQ ID NO:1). RTD-1 is a cationic, arginine-rich cyclic peptide containing 18 amino acids and three disulfide bonds between pairs of cysteines (Figure 1). Other active theta-defensin analogs are also shown in Figure 1.
[0040] The present inventors have identified a number of novel θ-defensin analogs that exhibit superior performance compared to MTD1280 (SEQ ID NO: 3) despite having similar covalent structures (e.g., length, cyclic structure, two pairs of disulfide bonds, and cationicity). Characteristics evaluated included survival benefit in antibiotic-resistant K. pneumoniae sepsis, biocompatibility (lack of toxicity), in vitro suppression of TNF-α (TNF) release, and inhibition of TACE. Amino acid sequences of exemplary cyclic peptides are shown in Table 1. It should be understood that the identity of the amino acids is indicated using the numerical designation of the corresponding positions within the cyclic structure established in FIG. 2. Properties and activities associated with these peptides are shown in Table 2.
[0041] [Table 1]
[0042] [Table 2]
[0043] Compared to these reference peptides, a number of sequence features were identified that confer superior activity to RTD-1 and MTD1280 derived analogs. All active theta-defensin analogs may possess at least the following: · Two disulfide bonds between Cys3 and Cys12 and between Cys5 and Cys10.
[0044] A hydrophobic amino acid located between Cys3 and Cys5 and between Cys10 and Cysl2 (i.e. positions 4 and 11) in the primary structure of the theta-defensin analogue, preferably leucine or isoleucine. In combination with the disulfide bond described above, this defines a feature in the cyclic primary structure of the peptide called a "CXC box", where "C" is cysteine and "X" is preferably either leucine or isoleucine.
[0045] In some embodiments, a CXC box comprising an arginine. A total of four arginine residues that give the peptide a +4 charge at physiological pH. Positions 6, 7, and 8, i.e. a triplet of adjacent arginines within the first β-turn.
[0046] In some embodiments, active theta-defensin analogs may also include one or more of the following features: Glycine at position 1 and glycine at position 13.
[0047] A hydrophobic amino acid at positions 2 and 9, preferably valine or phenylalanine. Arginine in the second β-turn (e.g., position 14). The toxicity of the candidate peptides suggests that an active θ-defensin analog should not contain one or more of the following: Alanine in fourth place.
[0048] Alanine at position 11. Thus, the inventors believe that a theta-defensin analogue containing the above-described "CXC box" structure, a triplet of adjacent arginine residues at positions 6, 7, and 8, a hydrophobic amino acid (e.g., valine or phenylalanine) at position 9, and having a net positive charge of +4 (approximately 28% of the total amino acid content) due to the arginine content, will be effective in reducing mortality and / or improving long-term survival in sepsis, and further will be effective in treating other conditions characterized by dysregulated inflammatory or immune responses.
[0049] The analogs of θ-defensin described herein can be administered using any suitable method. For example, such analogs can be provided by injection or infusion. The high degree of efficacy observed with some θ-defensin analogs indicates that they can be provided in effective amounts to individuals in need of treatment by simple subcutaneous, intradermal, subdermal, intravenous, and / or intramuscular injection.
[0050] Alternatively, the low molecular weight and high stability provided by the presence of cyclic structures and disulfide bonds can allow oral administration of the theta-defensin analog of the present invention. Such oral administration can include administration of a solution or suspension of the theta-defensin analog in a liquid pharmaceutical carrier suitable for oral administration. In some embodiments, the theta-defensin analog can be provided in a dried or lyophilized form that is reconstituted in a liquid medium prior to oral administration. Such dried or lyophilized formulations can include stabilizers. Suitable stabilizers include carbohydrates (e.g., mannitol, sucrose, trehalose) and / or proteins (e.g., albumin).
[0051] Alternatively, the analog of the θ-defensin can be provided in a tablet, capsule, pill, or other suitable solid and compact form suitable for oral administration. Such formulations can include a coating, shell, or similar component that provides delayed release of the θ-defensin analog (e.g., delays release until reaching the small intestine). Such formulations can include a liquid form of the θ-defensin within an enclosure or coating. Alternatively, such formulations can include the θ-defensin analog in a dried or lyophilized form. Suitable dried or lyophilized forms include powders, granules, and compressed solids. Such dried or lyophilized formulations can include a stabilizer. Suitable stabilizers include carbohydrates (e.g., mannitol, sucrose, trehalose) and / or proteins (e.g., albumin).
[0052] As described above, the theta-defensin analogs of the present invention can effectively treat sepsis and / or septic shock. In some embodiments, such treatment is responsive to an ongoing acute condition. In other embodiments, such treatment is prophylactic, for example, used to prevent the onset of septic shock when an individual is suspected of having sepsis or is likely to develop sepsis. Treatment can be provided by administering the theta-defensin analogs of the present invention on any suitable schedule. For example, the theta-defensin analogs can be provided as a single dose, a periodic dose, or a continuous infusion. Periodic doses can be administered at any suitable interval. Suitable intervals can be every hour, every two hours, every four hours, four times a day, three times a day, twice a day, once a day, every two days, every three days, twice a week, every week, every two weeks, every four weeks, every two months, every three months, every four months, three times a year, twice a year, or annually.
[0053] In some embodiments, the mode of administration of the theta-defensin analog can be altered during the course of treatment. For example, the theta-defensin analog of the inventive concept can be administered initially by intravenous injection or infusion (e.g., to rapidly provide effective concentrations in acute sepsis or septic shock), followed by intradermal injection, intramuscular injection, and / or oral administration to maintain effective concentrations for the remainder of the treatment period.
[0054] For prophylactic use, the θ-defensin analogs can be administered prior to the onset of observable symptoms. For the treatment of active diseases or conditions, the θ-defensin analogs can be administered for a period of time appropriate to effectively treat the disease or condition. Such periods can be for a controlled period of time or can be long term (e.g., for the treatment of chronic conditions).
[0055] In some embodiments of the inventive concept, the θ-defensin analogs may be used in combination with other pharmacologic active compounds. Suitable compounds include θ-defensins, different θ-defensin analogs, antibacterial antibiotics, antivirals, antifungal antibiotics, anti-inflammatory drugs (e.g., steroids, nonsteroidal anti-inflammatory drugs), hypertensives, and / or biologics (e.g., antibodies or antibody fragments). Such additional pharmaceutical compounds may be provided on the same schedule as the θ-defensin analogs, or on an independent schedule. In some embodiments, a θ-defensin analog-containing formulation incorporating one or more of such additional pharmacologic active compounds may be provided. The inventors believe that such combination therapy may provide a synergistic effect in which the cumulative effect of administration of the θ-defensin analog in combination with the additional pharmacologic active compounds exceeds the sum of the individual effects seen in treatment with the θ-defensin analog and the additional pharmacologic active compounds in amounts equivalent to those used in combination therapy.
[0056] It will be apparent to those skilled in the art that many more modifications beyond those already described are possible without departing from the inventive concepts herein. Accordingly, the subject matter of the present invention should not be limited except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context. In particular, the term "comprises" should be interpreted as referring to elements, components, or steps in a non-exclusive manner, indicating that a referenced element, component, or step may be present, utilized, or combined with other elements, components, or steps not expressly referenced. When the specification and claims refer to at least one selected from the group consisting of A, B, C.... and N, the context should be interpreted as requiring only one element from that group, and not A+N, B+N, etc.
Claims
1. It consists of 14 amino acids and has the following structure: 【Chemistry 1】 wherein AA3 and AA12 are cysteines linked by a disulfide bond, AA5 and AA10 are cysteines linked by a disulfide bond, AA4 is a first hydrophobic amino acid, AA11 is a second hydrophobic acid, AA6 is arginine, AA7 is arginine, and AA8 is arginine, with four arginine residues providing a positive charge of approximately 28% at physiological pH.
2. 2. The cyclic peptide of claim 1, wherein the first hydrophobic amino acid and the second hydrophobic amino acid are leucine or isoleucine.
3. 3. The cyclic peptide of claim 1 or 2, wherein AA1 is glycine.
4. The cyclic peptide of any one of claims 1 to 3, wherein AA2 is a third hydrophobic amino acid.
5. 5. The cyclic peptide of claim 4, wherein the third hydrophobic amino acid is valine or phenylalanine.
6. The cyclic peptide of any one of claims 1 to 5, wherein AA9 is the fourth hydrophobic amino acid.
7. 7. The cyclic peptide of claim 6, wherein the fourth hydrophobic amino acid is valine or phenylalanine.
8. The cyclic peptide of any one of claims 1 to 7, wherein AA13 is glycine.
9. The cyclic peptide of any one of claims 1 to 8, wherein AA14 is arginine.
10. The cyclic peptide of any one of claims 1 to 9, wherein AA4 is neither alanine nor serine.
11. The cyclic peptide of any one of claims 1 to 10, wherein AA11 is neither alanine nor serine.
12. The cyclic peptide of claim 1, which is MTD12813 (SEQ ID NO: 2).
13. The cyclic peptide of any one of claims 1 to 12, wherein the cyclic peptide is an analog of a theta-defensin, and when applied systemically to a mouse sepsis model, the cyclic peptide provides improved survival compared to theta-defensin.
14. The cyclic peptide of any one of claims 1 to 13, wherein the cyclic peptide provides a biphasic response when applied to a mouse model of sepsis, the biphasic response comprising a first phase of recruitment of host effector cells with antibacterial activity and a second phase of alleviation of the host inflammatory response.
15. A cyclic peptide according to any one of claims 1 to 14, having TACE inhibitory activity.
16. The cyclic peptide of any one of claims 1 to 15, which inhibits at least one of the expression, processing, and release of TNF.
17. A cyclic peptide according to any one of claims 1 to 16, which retains activity after exposure to extreme temperatures, low pH, freezing and / or thawing, and dissolution in biological matrices.
18. 18. The cyclic peptide of claim 17, wherein the biological matrix is selected from the group consisting of blood, plasma, and serum.
19. The cyclic peptide of any one of claims 1 to 18, wherein the cyclic peptide is non-immunogenic at a dose effective to treat or prevent sepsis and / or septic shock.
20. The cyclic peptide of any one of claims 1 to 18, which activates the host immune system to promote host pathogen clearance.
21. The cyclic peptide of any one of claims 1 to 20, characterized by inflammation modulating, disease resolution and survival enhancing activity at a dose effective for treating or preventing septic shock.
22. A method for treating or preventing septic shock comprising administering to an animal at risk of septic shock a cyclic peptide having the following structure: 【Chemistry 2】 wherein AA3 and AA12 are cysteines linked by a disulfide bond, AA5 and AA10 are cysteines linked by a disulfide bond, AA4 is a first hydrophobic amino acid, AA11 is a second hydrophobic acid, AA6 is arginine, AA7 is arginine, and AA8 is arginine, with four arginine residues providing a positive charge amount of about 28% at physiological pH.
23. 23. The method of claim 22, wherein the first hydrophobic amino acid and the second hydrophobic amino acid are leucine or isoleucine.
24. 24. The method of claim 22 or 23, wherein AA1 is glycine.
25. 25. The method of any one of claims 22 to 24, wherein AA2 is the third hydrophobic amino acid.
26. 26. The method of claim 25, wherein the third hydrophobic amino acid is valine or phenylalanine.
27. 27. The method of any one of claims 22 to 26, wherein AA9 is the fourth hydrophobic amino acid.
28. 28. The method of claim 27, wherein the fourth hydrophobic amino acid is valine or phenylalanine.
29. The method of any one of claims 22 to 28, wherein AA13 is glycine.
30. 30. The method of any one of claims 22 to 29, wherein AA14 is arginine.
31. The method of any one of claims 22 to 30, wherein AA4 is not alanine or serine.
32. The method of any one of claims 22 to 31, wherein AA11 is not alanine or serine.
33. 23. The method of claim 22, wherein the cyclic peptide is MTD12813 (SEQ ID NO: 2).
34. The method of any one of claims 22 to 33, wherein the cyclic peptide is an analog of a theta-defensin, and the cyclic peptide provides improved survival compared to theta-defensin when systemically applied to a mouse sepsis model.
35. 35. The method of any one of claims 22 to 34, wherein the method provides a biphasic response upon application to a mouse model of sepsis, the biphasic response comprising a first phase of recruitment of host effector cells with antimicrobial activity and a second phase of alleviation of the host inflammatory response.
36. The method of any one of claims 22 to 35, wherein TACE activity is inhibited.
37. 37. The method of any one of claims 22 to 36, wherein at least one of expression, processing, and release of TNF is inhibited.
38. The method of any one of claims 22 to 37, wherein the cyclic peptide retains activity after exposure to extreme temperatures, low pH, freezing and / or thawing, and dissolution in a biological matrix.
39. 39. The method of claim 38, wherein the biological matrix is selected from the group consisting of blood, plasma, and serum.
40. The method of any one of claims 22 to 39, wherein the cyclic peptide is non-immunogenic at a dose effective to treat or prevent septic shock.
41. The method of any one of claims 22 to 40, wherein the cyclic peptide activates the host immune system to promote pathogen clearance in the host.
42. 2. Use of a cyclic peptide in the treatment or prevention of sepsis and / or septic shock, said cyclic peptide having the following structure: 【Chemistry 3】 wherein AA3 and AA12 are cysteines linked by a disulfide bond, AA5 and AA10 are cysteines linked by a disulfide bond, AA4 is a first hydrophobic amino acid, AA11 is a second hydrophobic acid, AA6 is arginine, AA7 is arginine, and AA8 is arginine, said cyclic peptide having four arginine residues providing a positive charge amount of about 28% at physiological pH.
43. 43. The use of claim 42, wherein the first hydrophobic amino acid and the second hydrophobic amino acid are leucine or isoleucine.
44. 44. The use according to claim 42 or 43, wherein AA1 is glycine.
45. The use according to any one of claims 42 to 44, wherein AA2 is the third hydrophobic amino acid.
46. 46. The use according to claim 45, wherein the third hydrophobic amino acid is valine or phenylalanine.
47. The use according to any one of claims 42 to 46, wherein AA9 is the fourth hydrophobic amino acid.
48. 48. The use according to claim 47, wherein the fourth hydrophobic amino acid is valine or phenylalanine.
49. The use according to any one of claims 42 to 48, wherein AA13 is glycine.
50. 50. The use according to any one of claims 42 to 49, wherein AA14 is arginine.
51. The use according to any one of claims 42 to 50, wherein AA4 is not alanine or serine.
52. The use according to any one of claims 42 to 51, wherein AA11 is not alanine or serine.
53. 43. The use according to claim 42, wherein the cyclic peptide is MTD12813 (SEQ ID NO: 2).
54. The use of any one of claims 42 to 53, wherein the cyclic peptide is an analogue of a theta-defensin, and the cyclic peptide provides improved survival compared to theta-defensin when applied systemically in a mouse sepsis model.
55. 55. The use according to any one of claims 42 to 54, wherein the cyclic peptide provides a biphasic response when applied in a mouse model of sepsis, the biphasic response comprising a first phase of recruitment of host effector cells with antibacterial activity and a second phase of alleviation of the host inflammatory response.
56. The use according to any one of claims 42 to 55, wherein the cyclic peptide has TACE inhibitory activity.
57. The use according to any one of claims 42 to 56, wherein the cyclic peptide inhibits at least one of the expression, processing and release of TNF.
58. The use according to any one of claims 42 to 57, wherein the cyclic peptide retains activity after exposure to extreme temperatures, low pH, freezing and / or thawing, and dissolution in biological matrices.
59. 59. The use of claim 58, wherein the biological matrix is selected from the group consisting of blood, plasma, and serum.
60. The use according to any one of claims 42 to 59, wherein the cyclic peptide is non-immunogenic at a dose effective to treat or prevent septic shock.
61. The use according to any one of claims 42 to 60, wherein the cyclic peptide activates the host immune system to promote host pathogen clearance.
62. The use according to any one of claims 42 to 61, wherein the cyclic peptide is characterized by inflammation modulating, disease resolution and survival enhancing activity at a dose effective for treating or preventing septic shock.
63. 2. Use of a cyclic peptide in the preparation of a medicament for the treatment or prevention of septic shock, said cyclic peptide having the following structure: 【Chemistry 4】 wherein AA3 and AA12 are cysteines linked by a disulfide bond, AA5 and AA10 are cysteines linked by a disulfide bond, AA4 is a first hydrophobic amino acid, AA11 is a second hydrophobic acid, AA6 is arginine, AA7 is arginine, and AA8 is arginine, said cyclic peptide having four arginine residues providing a positive charge amount of about 30% at physiological pH.
64. 64. The use of claim 63, wherein the first hydrophobic amino acid and the second hydrophobic amino acid are leucine or isoleucine.
65. 65. The use according to claim 63 or 64, wherein AA1 is glycine.
66. 66. The use according to any one of claims 63 to 65, wherein AA2 is the third hydrophobic amino acid.
67. 67. The use of claim 66, wherein the third hydrophobic amino acid is valine or phenylalanine.
68. 68. The use according to any one of claims 63 to 67, wherein AA9 is the fourth hydrophobic amino acid.
69. 48. The use according to claim 47, wherein the fourth hydrophobic amino acid is valine or phenylalanine.
70. 70. The use according to any one of claims 63 to 69, wherein AA13 is glycine.
71. 71. The use according to any one of claims 63 to 70, wherein AA14 is arginine.
72. 72. The use according to any one of claims 63 to 71, wherein AA4 is not alanine or serine.
73. 73. The use according to any one of claims 63 to 72, wherein AA11 is not alanine or serine.
74. 74. The use according to claim 73, wherein the cyclic peptide is MTD12813 (SEQ ID NO: 2).
75. The use of any one of claims 63 to 74, wherein the cyclic peptide is an analogue of a theta-defensin, and the cyclic peptide provides improved survival compared to theta-defensin when applied systemically in a mouse sepsis model.
76. 76. The use according to any one of claims 63 to 75, wherein the cyclic peptide provides a biphasic response when applied in a mouse model of sepsis, the biphasic response comprising a first phase of recruitment of host effector cells with antifungal activity and a second phase of alleviation of the host inflammatory response.
77. The use according to any one of claims 63 to 76, wherein the cyclic peptide has TACE inhibitory activity.
78. The use according to any one of claims 63 to 77, wherein the cyclic peptide inhibits at least one of the expression, processing and release of TNF.
79. The use according to any one of claims 63 to 78, wherein the cyclic peptide retains activity after exposure to extreme temperatures, low pH, freezing and / or thawing, and dissolution in biological matrices.
80. 80. The use of claim 79, wherein the biological matrix is selected from the group consisting of blood, plasma, and serum.
81. The use according to any one of claims 63 to 80, wherein the cyclic peptide is non-immunogenic at a dose effective to treat or prevent septic shock.
82. The use according to any one of claims 63 to 81, wherein the cyclic peptide activates the host immune system to promote host pathogen clearance.
83. 83. The use according to any one of claims 63 to 82, wherein the cyclic peptide is characterized by inflammation modulating, disease resolution and survival enhancing activity at a dose effective for treating or preventing sepsis and / or septic shock.
Citation Information
Patent Citations
Cyclic peptides with broad-spectrum antibacterial activity
JP2001503020A
Thetadefensin blocks inflammatory proteases.
JP2014516990A
Novel theta defensin analogues
JP2022538854A
Antimicrobial theta defensins, analogs thereof, and methods of use
US20070015712A1
Cyclic beta defensins analogs for the treatment of infections
EP2990415A1
